Schiller J T, Lowy D R
Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD 20892, USA.
Semin Cancer Biol. 1996 Dec;7(6):373-82. doi: 10.1006/scbi.1996.0046.
Human papillomavirus-like particles (VLPs), self-assembled after high level expression of the papillomavirus L1 virion capsid protein in non-mammalian cells, are attractive candidates for a subunit vaccine to prevent genital HPV infection and the subsequent development of cervical cancer. In animal studies, purified VLPs induce high titers of antibodies against conformational type specific L1 epitopes. These antibodies neutralize homologous virions in in-vitro assays and protect against experimental challenge in several animal models. The encouraging results in animals justify the initiation of human trials of HPV VLP-based vaccines. Factors to be considered when designing these trials are discussed.
人乳头瘤病毒样颗粒（VLPs）是在非哺乳动物细胞中高水平表达乳头瘤病毒L1病毒体衣壳蛋白后自组装形成的，是预防生殖器HPV感染及后续宫颈癌发生的亚单位疫苗的有吸引力的候选物。在动物研究中，纯化的VLPs可诱导产生针对构象型特异性L1表位的高滴度抗体。这些抗体在体外试验中可中和同源病毒体，并在多种动物模型中抵御实验性攻击。动物实验中令人鼓舞的结果为启动基于HPV VLP疫苗的人体试验提供了依据。本文讨论了设计这些试验时需要考虑的因素。
